Justine Frame · Special Assistant, Policy, Health Canada (HC)
Sandenga Yeba · Director of Policy, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Free trade agreements as they relate to the biopharmaceutical industry.
Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Greg Orencsak · Deputy Minister, Health Canada (HC)
Sarah Lawley · Assistant Deputy Minister,, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Free trade agreements as they relate to the biopharmaceutical industry.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.Read more
Advocate for the implementation of a federal diabetes and obesity strategy.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.Read more
Support the establishment of a life sciences strategy in Canada
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.Read more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.